CFLAR and lung carcinoma: Hence, bortezomib or PCC as monotherapy showed moderate effects on c-FLIP inhibition, whereas combination treatment of bortezomib with PCC showed more significant inhibition of c-FLIP protein expression in all the three lung cancer cell lines (Figure 3b–d and Supplementary Figure S7).